BRPI0515104A - método para produzir todo-trans-(13,14)-diidrorretinol, polipeptìdeo isolado, polinucleotìdeo isolado, construção de expressão, célula procariótica ou eucariótica cultivada, vetor, célula hospedeira isolada, método para produzir um polipeptìdeo retsat, anticorpo, método para identificar agonistas ou antagonistas de um polipeptìdeo retsat eucariótico, composição farmacêutica, e, métodos para tratar uma doença neoplásica em um indivìduo mamìfero, para tratar doença retinal ou cegueira em um indivìduo mamìfero, para tratar um estado de doença retinal ou cegueira em um indivìduo mamìfero, para tratar doença auto imune em um indivìduo mamìfero e para tratar uma condição ou distúrbio de pele em um indivìduo mamìfero - Google Patents
método para produzir todo-trans-(13,14)-diidrorretinol, polipeptìdeo isolado, polinucleotìdeo isolado, construção de expressão, célula procariótica ou eucariótica cultivada, vetor, célula hospedeira isolada, método para produzir um polipeptìdeo retsat, anticorpo, método para identificar agonistas ou antagonistas de um polipeptìdeo retsat eucariótico, composição farmacêutica, e, métodos para tratar uma doença neoplásica em um indivìduo mamìfero, para tratar doença retinal ou cegueira em um indivìduo mamìfero, para tratar um estado de doença retinal ou cegueira em um indivìduo mamìfero, para tratar doença auto imune em um indivìduo mamìfero e para tratar uma condição ou distúrbio de pele em um indivìduo mamìferoInfo
- Publication number
- BRPI0515104A BRPI0515104A BRPI0515104-0A BRPI0515104A BRPI0515104A BR PI0515104 A BRPI0515104 A BR PI0515104A BR PI0515104 A BRPI0515104 A BR PI0515104A BR PI0515104 A BRPI0515104 A BR PI0515104A
- Authority
- BR
- Brazil
- Prior art keywords
- mammalian individual
- polypeptide
- treating
- disease
- isolated
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 101150089077 Retsat gene Proteins 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 201000004569 Blindness Diseases 0.000 title 2
- 208000017442 Retinal disease Diseases 0.000 title 2
- 210000004027 cell Anatomy 0.000 title 1
- FPIPGXGPPPQFEQ-DPZDGVIMSA-N dihydroretinol Natural products CC(=CCO)C=CC=C(C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-DPZDGVIMSA-N 0.000 title 1
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 210000001236 prokaryotic cell Anatomy 0.000 title 1
- 102100024731 All-trans-retinol 13,14-reductase Human genes 0.000 abstract 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
- 101710102933 All-trans-retinol 13,14-reductase Proteins 0.000 abstract 1
- 239000011717 all-trans-retinol Substances 0.000 abstract 1
- 229940100609 all-trans-retinol Drugs 0.000 abstract 1
- 235000019169 all-trans-retinol Nutrition 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002914 neoplasic effect Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
MéTODO PARA PRODUZIR TODO-TRANS-(13,14)-DIIDRORRETINOL, POLIPEPTìDEO ISOLADO, POLINUCLEOTìDEO ISOLADO, CONSTRUçãO DE EXPRESSãO, CéLULA PROCARIóTICA OU EUCARIóTICA CULTIVADA, VETOR, CéLULA HOSPEDEIRA ISOLADA, MéTODO PARA PRODUZIR UM POLIPEPTìDEO RETSAT, ANTICORPO, MéTODO PARA IDENTIFICAR AGONISTAS OU ANTAGONISTAS DE UM POLIPEPTìDEO RETSAT EUCARIóTICO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR UMA DOENçA NEOPLáSICA EM UM INDIVìDUO MAMìFERO, PARA TRATAR DOENçA RETINAL OU CEGUEIRA EM UM INDIVìDUO MAMìFERO, PARA TRATAR UM ESTADO DE DOENçA RETINAL OU CEGUEIRA EM UM INDIVìDUO MAMìFERO, PARA TRATAR DOENçA AUTOIMUNE EM UM INDIVìDUO MAMìFERO E PARA TRATAR UMA CONDIçãO OU DISTúRBIO DE PELE EM UM INDIVìDUO MAMìFERO Composições de todo todo-trans-retinol:todo-trans-13,14-diidrorretinol saturase e métodos de uso desta são fornecidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60903804P | 2004-09-09 | 2004-09-09 | |
| PCT/US2005/032462 WO2006029398A2 (en) | 2004-09-09 | 2005-09-09 | All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0515104A true BRPI0515104A (pt) | 2008-07-08 |
Family
ID=36037049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515104-0A BRPI0515104A (pt) | 2004-09-09 | 2005-09-09 | método para produzir todo-trans-(13,14)-diidrorretinol, polipeptìdeo isolado, polinucleotìdeo isolado, construção de expressão, célula procariótica ou eucariótica cultivada, vetor, célula hospedeira isolada, método para produzir um polipeptìdeo retsat, anticorpo, método para identificar agonistas ou antagonistas de um polipeptìdeo retsat eucariótico, composição farmacêutica, e, métodos para tratar uma doença neoplásica em um indivìduo mamìfero, para tratar doença retinal ou cegueira em um indivìduo mamìfero, para tratar um estado de doença retinal ou cegueira em um indivìduo mamìfero, para tratar doença auto imune em um indivìduo mamìfero e para tratar uma condição ou distúrbio de pele em um indivìduo mamìfero |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080249042A1 (pt) |
| EP (1) | EP1797176A2 (pt) |
| JP (1) | JP2008518586A (pt) |
| BR (1) | BRPI0515104A (pt) |
| MX (1) | MX2007002917A (pt) |
| WO (1) | WO2006029398A2 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063768A2 (en) * | 2006-10-12 | 2008-05-29 | Case Western Reserve University | Compositions and methods for treating metabolic diseases |
| WO2009133552A2 (en) | 2008-04-29 | 2009-11-05 | Nikken Sohonsha Corporation | Methods of treating ophthalmic disorders |
| US20100132059A1 (en) * | 2008-11-10 | 2010-05-27 | Wyeth Llc | Temperature-induced polynucleotides and uses therefor |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| US8889660B2 (en) | 2010-01-20 | 2014-11-18 | Case Western Reserve University | Methods for treating obesity or an obesity related condition |
| CN102531984B (zh) * | 2011-12-29 | 2013-12-04 | 上虞新和成生物化工有限公司 | 一种维生素a中间体的连续萃取提纯方法 |
| WO2016181288A1 (en) * | 2015-05-08 | 2016-11-17 | University Of Debrecen | Stereoselective synthesis of 9-cis.13,14-dihydroretinoic acid and its ethyl esters |
| US12029715B2 (en) * | 2015-05-08 | 2024-07-09 | University Of Debrecen | Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof |
| KR20190020661A (ko) * | 2016-04-28 | 2019-03-04 | 스파크 테라퓨틱스, 인코포레이티드 | 아이소메로하이드롤라아제를 인코딩하는 바이러스 벡터에 대한 상대 효능 검정 |
| CN121421999A (zh) * | 2025-11-26 | 2026-01-30 | 上海市松江区中心医院（上海交通大学附属第一人民医院松江分院） | Atdr和atdra在治疗脑白质病中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4463204A (en) * | 1983-04-22 | 1984-07-31 | Exxon Research & Engineering Co. | Process for alkylating toluene with methanol to form styrene using a low sodium content potassium/cesium modified zeolite catalyst composition |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4889818A (en) * | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| IL85018A0 (en) * | 1988-01-03 | 1988-06-30 | Orgenics Ltd | Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JPH02152196A (ja) * | 1988-12-03 | 1990-06-12 | Osaka Prefecture | 分散型ｅｌ素子 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| WO1991005754A2 (fr) * | 1989-10-13 | 1991-05-02 | Medafor | Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US20030032078A1 (en) * | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
-
2005
- 2005-09-09 BR BRPI0515104-0A patent/BRPI0515104A/pt not_active Application Discontinuation
- 2005-09-09 WO PCT/US2005/032462 patent/WO2006029398A2/en not_active Ceased
- 2005-09-09 US US11/574,976 patent/US20080249042A1/en not_active Abandoned
- 2005-09-09 MX MX2007002917A patent/MX2007002917A/es not_active Application Discontinuation
- 2005-09-09 JP JP2007531434A patent/JP2008518586A/ja not_active Abandoned
- 2005-09-09 EP EP05807306A patent/EP1797176A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007002917A (es) | 2007-07-11 |
| WO2006029398A3 (en) | 2009-05-07 |
| WO2006029398A8 (en) | 2006-06-01 |
| WO2006029398A2 (en) | 2006-03-16 |
| JP2008518586A (ja) | 2008-06-05 |
| EP1797176A2 (en) | 2007-06-20 |
| US20080249042A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mogessie et al. | Assembly and positioning of the oocyte meiotic spindle | |
| Kreeger et al. | The in vitro regulation of ovarian follicle development using alginate-extracellular matrix gels | |
| BRPI0515104A (pt) | método para produzir todo-trans-(13,14)-diidrorretinol, polipeptìdeo isolado, polinucleotìdeo isolado, construção de expressão, célula procariótica ou eucariótica cultivada, vetor, célula hospedeira isolada, método para produzir um polipeptìdeo retsat, anticorpo, método para identificar agonistas ou antagonistas de um polipeptìdeo retsat eucariótico, composição farmacêutica, e, métodos para tratar uma doença neoplásica em um indivìduo mamìfero, para tratar doença retinal ou cegueira em um indivìduo mamìfero, para tratar um estado de doença retinal ou cegueira em um indivìduo mamìfero, para tratar doença auto imune em um indivìduo mamìfero e para tratar uma condição ou distúrbio de pele em um indivìduo mamìfero | |
| BRPI0412637A (pt) | anticorpos, método de seleção de um anticorpo de hvegf, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, método de uso do anticorpo e método de tratamento de um mamìfero | |
| GEP20146050B (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| Vasserot et al. | Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options | |
| AR080564A1 (es) | Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) | |
| BRPI0417266B8 (pt) | anticorpo monoclonal, seu uso e composição farmacêutica | |
| ATE159429T1 (de) | Methode zum überbringen von agenzien an zielzellen | |
| BR0213996A (pt) | Método e aparelho para estimular o crescimento capilar | |
| CO5590971A2 (es) | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina | |
| Fraser | Cellular biology of capacitation and the acrosome reaction | |
| Frangoulis et al. | Rat epigastric flap survival and VEGF expression after local copper application | |
| BRPI0513135A (pt) | bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo | |
| BRPI0413813A (pt) | método para controlar a divisão de uma proteìna recombinante entre o sobrenadante e o periplasma em culturas de células hospedeiras de e. coli, anticorpo, fragmento de anticorpo, e, método para produzir uma proteìna recombinante em culturas de células hospedeiras de e. coli | |
| WO2020225799A3 (en) | A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein | |
| AU1955899A (en) | Mammalian edg-7 receptor homologs | |
| Brazıs et al. | Stem cell factor enhances IgE-mediated histamine and TNF-α release from dispersed canine cutaneous mast cells | |
| UY40023A (es) | Métodos de cultivo celular sin alimentadora para la expansión de preparaciones de células destructoras naturales | |
| Lefièvre et al. | Communication between female tract and sperm: Saying NO• when you mean yes | |
| Baek et al. | Identification of capacitation inducers customized to sperm retrieved from inbred mouse epididymis | |
| Fan et al. | Application of amphiregulin in IVM culture of immature human oocytes and pre-insemination culture for COCs in IVF cycles | |
| Ledwon et al. | Hippo Pathway Regulates Cell Proliferation in Skin Epidermis Exposed to Mechanical Forces | |
| MX2024003411A (es) | Métodos para controlar la heterogeneidad de anticuerpos. | |
| Uribe et al. | Impact of peroxynitrite-mediated nitrosative stress on human sperm cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |